Immunotherapy of cancer with allogeneic lymphocytes
AssigneesHadasit Medical Research Services and Development Ltd., Baxter International Inc.
InventorShimon Slavin
Life of this patent
Estimating the term…
Abstract
Methods have been discovered for treating residual disease following removal of most or a substantial fraction of malignant cells from a cancer patient. An autologous stem cell transplant is performed on the patient. Following partial hematopoiesis recovery, the patient is infused with allogeneic peripheral blood lymphocytes, either alone or in combination with in vivo or in vitro T-cell activation. The infused allogeneic lymphocytes engender and anti-malignant cell response.
Claims22
A method of treating a human cancer patient having malignant breast cancer cells, said patient having undergone a malignant cell debulking procedure and having further undergone autologous stem cell transplantation incident to said debulking procedure, said patient being at risk for disease relapse due to a population of residual malignant breast cancer cells that may remain viable in said patient following said debulking procedure, comprising:
- a) monitoring said patient until said patient is partially hematopoiesis recovered but is not fully immune-reconstituted;
- b) administering to said patient allogeneic lymphocytes in a regimen that causes a clinically significant graft-versus-malignant cell response;
- and
- c) monitoring said patient for levels of malignant breast cancer cells.
A method of treating a human cancer patient having malignant breast cancer cells, said patient having undergone a malignant cell debulking procedure and having further undergone autologous stem cell transplantation incident to said debulking procedure, said patient being at risk for disease relapse due to a population of residual malignant breast cancer cells that may remain viable in said patient following said debulking procedure, comprising:
- a) monitoring said patient until said patient is partially hematopoiesis recovered but is not fully immune-reconstituted;
- b) administering to said patient allogeneic lymphocytes in a regimen that causes a mild graft-versus-host response;
- and
- c) monitoring said patient for levels of malignant breast cancer cells.
The method of claim 21, wherein said selected lymphocytes are CD8+ lymphocytes.
Dependencies are inferred from the claim text.